Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626566 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL29286850 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL12310499 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL8988303 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL3624930 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL11666759 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL13512922 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL12339680 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL13632463 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL3626994 | 1.00 | ALDH1A1 (0.81) | ALDH1A1TDP1LMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5929094-A | NOVEL 3-((SUBSTITUTED) HETEROCYCLE),6-(SUBSTITUTED PHENYL)-1-OXASPIRO(4.4)NONANE DERIVATIVES; ANTAGONIZING THE EFFECT OF SUBSTANCE P BY ADMINISTERING TO BLOCK NEUROKININ-1 RECEPTORS; TREATING INFLAMMATION, MIGRAINE, EMESIS AND ASTHMA | MERCK & CO., INC. (US) | 1999-07-27 | — | — | US | claimed |
| US-12584015-B2 | Polyimide resin composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-03-24 | — | — | US | disclosed |
| US-12447717-B2 | Multilayered body and method for manufacturing same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-10-21 | — | — | US | disclosed |
| US-12195627-B2 | Polyimide resin composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2025-01-14 | — | — | US | disclosed |
| US-12139583-B2 | Resin molding | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-11-12 | — | — | US | disclosed |
| CN-117043232-B | Method for producing polyimide resin powder | 三菱瓦斯化学株式会社 | 2024-10-22 | — | — | CN | disclosed |
| US-20240199810-A1 | METHOD FOR PRODUCING POLYIMIDE RESIN POWDER | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-06-20 | — | — | US | disclosed |
| US-12006420-B2 | Polyimide powder composition | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-06-11 | — | — | US | disclosed |
| EP-4317254-A1 | METHOD FOR PRODUCING POLYIMIDE RESIN POWDER | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117043232-A | Method for producing polyimide resin powder | 三菱瓦斯化学株式会社 | 2023-11-10 | — | — | CN | disclosed |
| EP-1339402-B1 | AZAPHENANTHRIDONE DERIVATIVES AND THEIR USE AS PARP INHIBITORS | EISAI INC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-7718157-B1 | Targeted lipid particles | BAKER TERENCE SEWARD | 2010-05-18 | — | — | US | disclosed |
| US-7367419-B2 | Oxygen concentration sensor for a saddle ride type all-terrain vehicle | HONDA MOTOR CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-5929094-A | NOVEL 3-((SUBSTITUTED) HETEROCYCLE),6-(SUBSTITUTED PHENYL)-1-OXASPIRO(4.4)NONANE DERIVATIVES; ANTAGONIZING THE EFFECT OF SUBSTANCE P BY ADMINISTERING TO BLOCK NEUROKININ-1 RECEPTORS; TREATING INFLAMMATION, MIGRAINE, EMESIS AND ASTHMA | MERCK & CO., INC. (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0143396-B1 | CRYSTALLITE SUSPENSIONS OF CRYSTALLINE, ETHYLENICALLY UNSATURATED POLYESTERS AND POLYHYDROXYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PREPARATING POLYURETHANES OR POLYMERS CONTAINING POLYURETHANE GROUPS | BASF Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | disclosed |
| US-4560708-A | Polyisocyanurate/polyurethane elastomers based on suspensions of crystalline polyesters and polyhydroxyl compounds | BASF AKTIENGESELLSCHAFT (DE) | 1985-12-24 | — | — | US | disclosed |
| EP-0143396-A2 | Crystallite suspensions of crystalline, ethylenically unsaturated polyesters and polyhydroxyl compounds, process for their preparation and their use in preparating polyurethanes or polymers containing polyurethane groups | BASF Aktiengesellschaft (DE) | 1985-06-05 | — | — | EP | disclosed |
| US-4318979-A | COMBINATION TETRAZOLIUM SALT | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1982-03-09 | — | — | US | disclosed |
| US-4310683-A | Sulfosuccinate diesters | WITCO CHEMICAL CORPORATION (US) | 1982-01-12 | — | — | US | disclosed |
| US-4154955-A | Sulfosuccinate ester-amides | WITCO CHEMICAL CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584015-B2 | Polyimide resin composition | PSMA1, SEM1, RIF1 | ALDH1A1 1879/4885TDP1 927/4885LMNA 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.